136 related articles for article (PubMed ID: 37427705)
1. Role of individual factor X concentrate pharmacokinetic studies in perioperative management of AL amyloidosis-associated acquired factor X deficiency.
Lewis AR; Peffley N; Klompas AM; Ashrani AA
Transfusion; 2023 Sep; 63(9):1773-1777. PubMed ID: 37427705
[TBL] [Abstract][Full Text] [Related]
2. Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis.
Dejhansathit S; Suvannasankha A
J Investig Med High Impact Case Rep; 2019; 7():2324709619832332. PubMed ID: 30947547
[TBL] [Abstract][Full Text] [Related]
3. Plasma-derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency.
Escobar MA; Kavakli K
Haemophilia; 2024 Jan; 30(1):59-67. PubMed ID: 37902395
[TBL] [Abstract][Full Text] [Related]
4. Plasma-derived human factor X concentrate for on-demand and perioperative treatment in factor X-deficient patients: pharmacology, pharmacokinetics, efficacy, and safety.
Shapiro A
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):97-104. PubMed ID: 27797267
[TBL] [Abstract][Full Text] [Related]
5. Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease.
Patel G; Hari P; Szabo A; Rein L; Kreuziger LB; Chhabra S; Dhakal B; D'Souza A
Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):10-14. PubMed ID: 30879471
[TBL] [Abstract][Full Text] [Related]
6. Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients.
Thompson CA; Kyle R; Gertz M; Heit J; Pruthi R; Pardanani A
Am J Hematol; 2010 Mar; 85(3):171-3. PubMed ID: 20052750
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, clinical characteristics and treatment outcome of factor X deficiency in a consecutive cohort of primary light-chain amyloidosis.
Gao YJ; Shen KN; Chang L; Feng J; Mao YY; Zhang L; Cao XX; Zhou DB; Li J
Leuk Res; 2022 Sep; 120():106917. PubMed ID: 35849875
[TBL] [Abstract][Full Text] [Related]
8. Acute deep vein thrombosis with concurrent new diagnosis of AL-amyloid-induced factor X deficiency.
Paton EL; Barisic S; Sabile JM; Medvedova E
BMJ Case Rep; 2024 Jun; 17(6):. PubMed ID: 38839408
[TBL] [Abstract][Full Text] [Related]
9. Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery.
Escobar MA; Auerswald G; Austin S; Huang JN; Norton M; Millar CM
Haemophilia; 2016 Sep; 22(5):713-20. PubMed ID: 27217097
[TBL] [Abstract][Full Text] [Related]
10. Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
Marcatti M; Mauri S; Tresoldi M; Sabbadini MG; Vigano'D'Angelo S; Safa O; Rugarli C; D'Angelo A
Thromb Res; 1995 Nov; 80(4):333-7. PubMed ID: 8585046
[TBL] [Abstract][Full Text] [Related]
11. Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding.
Mar E; Taylor K; Mollee P
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33827877
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency.
Austin SK; Kavakli K; Norton M; Peyvandi F; Shapiro A;
Haemophilia; 2016 May; 22(3):419-25. PubMed ID: 27197801
[TBL] [Abstract][Full Text] [Related]
13. Occurrence and management of severe bleeding episodes in patients with hereditary factor X deficiency.
Tarantino MD
Haemophilia; 2021 Jul; 27(4):531-543. PubMed ID: 34021672
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency.
Austin SK; Brindley C; Kavakli K; Norton M; Shapiro A;
Haemophilia; 2016 May; 22(3):426-32. PubMed ID: 26879266
[TBL] [Abstract][Full Text] [Related]
15. Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis.
Mahmood S; Blundell J; Drebes A; Hawkins PN; Wechalekar AD
Blood; 2014 May; 123(18):2899-900. PubMed ID: 24786460
[No Abstract] [Full Text] [Related]
16. Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency.
Kulkarni R; James AH; Norton M; Shapiro A
J Thromb Haemost; 2018 May; 16(5):849-857. PubMed ID: 29460388
[TBL] [Abstract][Full Text] [Related]
17. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis.
Mumford AD; O'Donnell J; Gillmore JD; Manning RA; Hawkins PN; Laffan M
Br J Haematol; 2000 Aug; 110(2):454-60. PubMed ID: 10971408
[TBL] [Abstract][Full Text] [Related]
18. Successful perioperative management of factor X deficiency associated with primary amyloidosis.
Takabe K; Holman PR; Herbst KD; Glass CA; Bouvet M
J Gastrointest Surg; 2004; 8(3):358-62. PubMed ID: 15019934
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic treatment of bleeding episodes in children <12 years with moderate to severe hereditary factor X deficiency (FXD): Efficacy and safety of a high-purity plasma-derived factor X (pdFX) concentrate.
Liesner R; Akanezi C; Norton M; Payne J
Haemophilia; 2018 Nov; 24(6):941-949. PubMed ID: 29707881
[TBL] [Abstract][Full Text] [Related]
20. Presurgical plasma exchange is ineffective in correcting amyloid associated factor X deficiency.
Barker B; Altuntas F; Paranjape G; Sarode R
J Clin Apher; 2004; 19(4):208-10. PubMed ID: 15597349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
